Dongwha's Milikan, an anti-liver cancer drug, approved.
For the 3rd time of its history of domestic new drug development, Dongwha pharmaceutical company obtained the KFDA approval on July 6 over the new anti-liver cancer injectable drug, Milikan.
According to the KFDA, Dongwha has made about 4,300 million won of R&D investment from 1995 in a join...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
